Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis

Li Dong; Luo TianYang; Ran YaWei

doi:10.3969/j.issn.1001-5256.2019.10.017

Volume 35 Issue 10

Oct. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(10): 2214-2219

PDF( 1323 KB)

Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.10.017

Imaging Center,The First people's Hospital of Baiyin

Received Date: 2019-05-27
Published Date: 2019-10-20

Abstract

Abstract

Objective To systematically evaluate the value of contrast-enhanced computed tomography(CECT) and contrast-enhanced magnetic resonance imaging(CEMRI) in the diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization(TACE)in hepatocellular carcinoma(HCC). Methods Pub Med,Embase,Cochrane Library,Web of Science,CNKI,and Wanfang Data were searched for studies on CECT and/or CEMRI in the diagnosis of residual or recurrent lesion after TACE published up to April 2019. After two reviewers independently performed literature screening,data extraction,and assessment of the risk of bias using the QUADAS-2 tool,Stata 12. 0 and Rev Man 5. 3 were used to analyze pooled sensitivity,specificity,and area under the receiver operator characteristic curve(AUC). Results A total of 13 studies on CECT and 13 studies on CEMRI in the diagnosis of residual or recurrent HCC lesion after TACE were included,with 934 lesions from 748 patients and 847 lesions from 557 patients,respectively. High heterogeneity was observed in the 13 studies on CECT in the diagnosis of residual or recurrent HCC lesion after TACE(P = 0. 001,Q = 12. 56,I2= 84. 08%),while no significant heterogeneity was observed in the 13 studies on CEMRI(P = 0. 473,Q = 0. 11,I2= 0). In the diagnosis of residual or recurrent HCC lesion after TACE,CECT had a sensitivity of 72%(95% confidence interval [CI]: 66%-78%),a specificity of 99%(95% CI: 93%-100%),and an AUC of 0. 87(95% CI: 0. 83-0. 89),and CEMRI had a sensitivity of 88%(95% CI: 82%-93%),a specificity of 96%(95% CI: 91%-98%),and an AUC of 0. 98(95% CI: 0. 96-0. 99). CECT had a significantly lower sensitivity than CEMRI in the diagnosis of residual or recurrent HCC lesion after TACE(Z = 2. 12,P = 0. 03). Conclusion In comparison with CECT,CEMRI has an extremely higher diagnostic efficiency in the diagnosis of residual or recurrent HCC lesion after TACE and is thus an effective method for diagnosis.
- carcinoma,hepatocellular,
- tomography,X-Ray computed,
- magnetic resonance imaging,
- Meta-analysis as topic

FullText(HTML)

References(34)

References

[1] Chinese College of Interventionalists. Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. J Intervent Radiol,2018,27(12):1117-1126.(in Chinese)中国医师协会介入医师分会．中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]．介入放射学杂志，2018,27(12):1117-1126.

[2] PAGE AJ,COSGROVE DC,PHILOSCOPHE,et al. Hepatocellular carcinoma:Diagnosis,management,and prognosis[J]. Surg Oncol Clin N Am,2014,23(2):289-311.

[3] WHITING PF,RUTIES AW,WESTWOOD ME,et al. QUADAS-2:A revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med,2011,158(8):529-536.

[4] CHO YZ,PARK SY,CHOI EH,et al. The usefulness of contrastenhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization:Pilot study[J]. Clin Mol Hepatol,2015,21(2):165-174.

[5] CHOI SJ,KIM J,SEO J,et al. Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization[J]. Euro Radiol,2016,26(1):225-234.

[6] JANG KM,CHOI D,LIM HK,et al. Depiction of viable tumor in hepatocellular carcinoma treated with transarterial chemoembolization:Multiphasic helical CT with review of the previous serial CT images[J]. Korean J Radiol,2005,6(3):153-160.

[7] KIM HJ,KIM TK,KIM PN,et al. Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization:Comparison of enhanced sonography and 3-phase computed tomography[J].J Ultrasound Med,2006,25(4):477-486.

[8] LIU M,LIN MX,LU MD,et al. Comparison of enhanced ultrasound and computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST[J]. Euro Radiol,2015,25(8):2502-2511.

[9] PAUL SB,DHAMIJA E,GAMANAGATTI SR,et al. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma:Comparison of contrast-enhanced ultrasound with MSCT[J]. Diagn Interv Imaging,2017,98(3):253-260.

[10] SALVAGGION G,CAMPISI A,GRECO V,et al. Evaluation of posttreatment response of hepatocellular carcinoma:Comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT[J]. Abdom Imaging,2010,35(4):447-453.

[11] SHANG JB,LIU FY,LI YH,et al. A comparative study of 18F-FDG PET,CT and angiography in the follow up of primary liver carcinoma after transarterial chemoembolization[J]. J Chin Clin Med Imaging,2004,15(9):509-512,529.(in Chinese)商健彪，刘方颖，李彦豪，等．(18)F-FDG PET、CT和血管造影在原发性肝癌TACE后随访的对比研究[J]．中国临床医学影像杂志，2004,15(9):509-512,529.

[12] SI XW,ZHOU HL,CHEN HP,et al. Evaluation of the effect of MRI and CT in primary hepatocellular carcinoma after TACE[J].Med J West China,2017,29(8):1150-1153.(in Chinese)斯兴无，周红俐，陈华平，等．MRI与CT对原发性肝癌TACE术后的疗效评估[J]．西部医学，2017,29(8):1150-1153.

[13] TAKIZAWA K,NUMATA K,MORIMOTO M,et al. Use of contrast-enhanced ultrasonography with a contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable HCC[J]. Euro J Radiol,2013,82(9):1471-1480.

[14] WANG X,LI D,HE F,et al. Contrastive analysis of contrastenhanced ultrasound and enhanced CT in evaluating the efficacy of TACE in the treatment of primary liver cancer[J]. Hebei Med,2018,24(7):1113-1116.(in Chinese)王曦，李东，何芬，等．超声造影与增强CT评估TACE治疗原发性肝癌疗效的价值对比[J]．河北医学，2018,24(7):1113-1116.

[15] XIANG K,ZHAO HL,ZHENG CY,et al. Comparison of assessment value of 16-slice spiral CT and MRI for lesions of primary hepatic carcinoma after TACE surgery[J]. Pract J Cancer,2014,29(10):1315-1317,1321.(in Chinese)项昆，赵鹤亮，郑昌英，等．16排螺旋CT和MRI对原发性肝癌TACE术后病灶的疗效判断价值对比[J]．实用癌症杂志，2014,29(10):1315-1317,1321.

[16] YANG ML,YANG ZY,XIE CM. Comparative study on digital substraction angiography and CT diagnosis for the residual and new lesions of PHC after transcatheter arterial chemoembolization[J]. Cancer Res Clin,2014,26(3):145-147,152.(in Chinese)杨敏玲，杨志勇，谢春明．原发性肝癌经导管肝动脉化疗栓塞术后肿瘤残留及新发病灶的CT和数字减影血管造影诊断对比研究[J]．肿瘤研究与临床，2014,26(3):145-147,152.

[17] BOLOG N,PFAMMATTER T,MULLHAUPT B,et al. Doublecontrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization[J]. Abdom Imaging,2008,33(3):313-323.

[18] CEN YM,LIANG JW,TANG XY,et al. Comparison of CT and MR scan for primary hepatic carcinoma after TACE[J]. J Hepatobiliary Surg,2016,24(5):347-350.(in Chinese)岑裕铭，梁甲伟，唐小勇，等．原发性肝癌TACE术后活性灶的CT和MR对比较[J]．肝胆外科杂志，2016,24(5):347-350.

[19] FENG DP,LI NA,WANG XC,et al. Value of MRI in assessing residual tumor of hepatocellular carcinoma in patients with accumulation deposition of lipiodol after TACE[J/CD]. Chin J Inter Rad:Electronic Edition,2014,2(3):6-19.(in Chinese)冯对平，李丽娜，王效春，等．肝癌碘油栓塞后沉积良好患者的MRI随访临床研究[J/CD]．中华介入放射学电子杂志，2014,2(3):6-19.

[20] GOSHIMA S,KANEMATSU M,KONDO H,et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization:Is diffusion-weighted MRI reliable as an indicator?[J]. J Magn Reson Imaging,2008,27(4):834-839.

[21] GUO CG,ZHANG JF,XU SL,et al. Diffusion weighted imaging combined with dynamic contrast enhanced magnetic resonance imaging in monitoring therapeutic efficacy for hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. J Zhejiang Uuiversity:Medical Science,2014,43(1):77-82,88.(in Chinese)过川根，张景峰，许顺良．磁共振弥散加权成像联合动态增强在肝癌患者TACE术后病灶残留及复发监测中的应用价值[J]．浙江大学学报:医学版，2014,43(1):77-82,88.

[22] KALB B,CHAMSUDDIN A,NAZAAL L,et al. Chemoembolization follow-up of hepatocellular carcinoma with MR imaging:Usefulness of evaluating enhancement features on onemonth posttherapy MR imaging for predicting residual disease[J]. J Vasc Interv Radiol,2010,21(9):1396-1404.

[23] LIU R,WANG JH,ZHOU KR,et al. A comparative study of CT and MRI in the follow-up of hepatocellular carcinoma after transcatheter arterial chemoembolization with lipiodol[J]. J Practical Radiology,2003,19(10):902-905.(in Chinese)刘嵘，王建华，周康荣，等．原发性肝癌TACE后CT和MRI随访的对照研究[J]．实用放射学杂志，2003,19(10):902-905.

[24] PAN L,ZHENG DW. Evaluation of MSCT and MRI on the postoperatively curative effect of TACE for patient with PHC[J].China Med Equipment,2018,15(8):45-48.(in Chinese)潘利，郑大伟．多层螺旋CT与磁共振成像对原发性肝癌经肝动脉化疗栓塞术后疗效评价[J]．中国医学装备，2018,15(8):45-48.

[25] WEI J,DUAN Q,XUE YJ,et al. Dynamic contrast-enhanced VIBE sequence at 3. 0T MR:Assessment of therapeutic effect of transcatheter arterial chemoembolization for hepatocellucer carcinoma[J]. Chin J Interv Imaging,2008,5(2):115-118.(in Chinese)威晋，段青，薛蕴菁，等．3. 0T VIBE序列动态增强磁共振检查在评估经导管肝动脉化疗栓塞术治疗肝细胞癌疗效中的价值[J]．中国介入影像与治疗学，2008,5(2):115-118.

[26] YANG YW,WANG ZT,WANG Y,et al. MR diffusion weighted imaging in the prognosis evaluation of liver cancer after treatment of transcatheter arterial chemoembolization[J]. J Pract Radiol,2018,34(4):600-602,605.(in Chinese)杨耀文，王志涛，王颖．MR DWI在肝癌TACE术后评估中的应用研究[J]．实用放射学杂志，2018,34(4):600-602,605.

[27] YANG ZC. Clinical analysis of CT and MRI in evaluating tumor residual and lesion stability after primary hepatocellular carcinoma with TACE[J]. Inter Med Health Guid News,2014,20(4):512-514.(in Chinese)杨忠诚．CT和MRI评价原发性肝癌TACE治疗后肿瘤残存和病灶稳定性的临床分析[J]．国际医药卫生导报，2014,20(4):512-514.

[28] YIM JH,KIM YK,Min JH,et al. Diagnosis of recurrent HCC:Intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI[J]. Abdom Radiol(NY),2019,44(7):2366-2376.

[29] ZHAO LF,WANG CS,ZHANG YF,et al. Preliminary study of CT perfusion and MRI of hepatocelluar carcinoma after fist transcatheter chemoem-bolization with lipiodol[J]. Chin J Misdiag,2009,9(16):3783-3785.(in Chinese)赵立峰，王昌生，张妍芬，等．原发性肝癌首次TACE术后CT灌注与MRI的研究初探[J]．中国误诊学杂志，2009,9(16):3783-3785.

[30] WALLACE MC,PREEN D,JEFFREY GP,et al. The evolving epidemiology of hepatocellular carcinoma:A global perspective[J]. Expert Rev Gastroenterol Hepatol,2015,9(6):765-779.

[31] BRAY F,FERALY J,SOERJOMATARAM,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[32] KIM J,CHOI SJ,LEE SH,et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization:Comparison of models using radiomics[J]. AJR Am J Roentgenol,2018,211(5):1026-1034.

[33] LIU HF,XU YS,ZHANG Y,et al. Value of magnetic resonance morphological imaging in the diagnosis and differentiation of post-hepatitis B cirrhosis[J]. J Clin Hepatol,2018,34(12):2587-2591.(in Chinese)刘海峰，许永生，张跃，等．MR形态学成像在乙型肝炎肝硬化诊断及分期中的应用价值[J]．临床肝胆病杂志，2018,34(12):2587-2591.

[34] LEITAO HS,DOBLAS S,GARTEISER P,et al. Hepatic fibrosis,inflammation,and steatosis:Influence on the MR Viscoelastic and diffusion parameters in patients with chronic liver disease[J]. Radiology,2017,283(1):98-107.

Relative Articles

[1]	Liu Li, Jiang YingYi, Liu Jing. Glucose metabolism and insulin secretion in patients with chronic hepatitis B cirrhosis of different Child-Pugh grades and their association with inflammatory response[J]. Journal of Clinical Hepatology, 2020, 36(2): 324-328. doi: 10.3969/j.issn.1001-5256.2020.02.018
[2]	Wu QiQi, Ma Yan, Wang XiaoBo, Xu Qiang, Wang Yan, Bai Li. Influence of metabolic syndrome on significant hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(12): 2572-2577. doi: 10.3969/j.issn.1001-5256.2018.12.013
[3]	He YuLan, Sun Lin, Yu HongWei, Meng QingHua. Expression of glucose transporter 2 in liver tissue in patients with hepatogenous diabetes and its significance[J]. Journal of Clinical Hepatology, 2017, 33(3): 512-515. doi: 10.3969/j.issn.1001-5256.2017.03.023
[4]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Clinical features of acute hepatitis B and acute exacerbation of chronic hepatitis B: a comparative study[J]. Journal of Clinical Hepatology, 2016, 32(4): 706-710. doi: 10.3969/j.issn.1001-5256.2016.04.019
[5]	Ruan JianWen, Gao LiJuan, Su RuKai. Clinical features of patients with acute exacerbation of chronic hepatitis B: an analysis of 74 cases[J]. Journal of Clinical Hepatology, 2016, 32(11): 2096-2098. doi: 10.3969/j.issn.1001-5256.2016.11.017
[6]	Xun YunHao, Guo JianChun. Clinical application of traditional Chinese medicine constitution theory in diagnosis and treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(4): 644-648. doi: 10.3969/j.issn.1001-5256.2016.04.006
[7]	Zhang ZeTian, Ji HuiFan, Chen Shuai, Li Xu, Yang WenXuan, Zhang GuoShan, Guo XiaoLin. Clinical cure of chronic hepatitis B: a case report[J]. Journal of Clinical Hepatology, 2016, 32(8): 1578-1579. doi: 10.3969/j.issn.1001-5256.2016.08.030
[8]	Zhang WenJie, Chen QiDan, Wan Yu, Deng Hui. Clinical features of male patients with alcoholic liver cirrhosis or hepatitis B cirrhosis complicated by abnormal glucose metabolism[J]. Journal of Clinical Hepatology, 2016, 32(2): 296-300. doi: 10.3969/j.issn.1001-5256.2016.02.020
[9]	Gao YueQiu. Strategy for traditional Chinese medicine prevention and treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(1): 35-37. doi: 10.3969/j.issn.1001-5256.2015.01.008
[10]	Peng Hong, Yang Jian, Mai RunZhang, Chen HongTao. Relationship between serum adiponectin level and metabolic indices in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(4): 354-356. doi: 10.3969/j.issn.1001-5256.2014.04.016
[11]	Zhang LiHang, Mao JunLing, Ren HaiFeng, Wang ShanJuan, Zhang Hui, Wan Jian, Liu YanLi, Wang YiFei, Lin YongHui. Relationship between glucose metabolism and hepatic encephalopathy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(7): 532-534. doi: 1001-5256 (2013) 07-0532-03
[12]	Hepatobiliary Disease Group, Internal Medicine of Traditional Chinese, China Association of Traditional Chinese Medicine, Expert Consensus of Hepatology, World Federation of Chinese Medicine Societies, Hepatology Group, Chinese Association of the Integration of Traditional and Western Medicine. Guidelines for traditional Chinese medical diagnosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2012, 28(3): 164-168.
[13]	Zhu QiRong. Nosocomial infections and chronic severe hepatitis B: A clinical study of 162 patients[J]. Journal of Clinical Hepatology, 2012, 28(7): 525-527.
[14]	Li ChunXia, Pan HuaiQiang, Li YanJun, Xu GuangHua, Chen YanPing, Feng JiHong, Wei Hua, Ceng QingLei. One case report of occult hepatitis B infection[J]. Journal of Clinical Hepatology, 2012, 28(1): 66-68.
[15]	Yang Song, Cheng Jun. Interpretation of Chinese guideline on prevention and treatment for chronic hepatitis B (2011version) -status quo and prospect of antiviral therapy[J]. Journal of Clinical Hepatology, 2011, 27(8): 794-795+800.
[16]	Qiu YingFeng, Ding YongGang, Li GuangMing. Analysis of therapeutic effect of adefovir dipivoxil in continued treatment of chronic hepatitis B patients with poor early virological response to initial treatment[J]. Journal of Clinical Hepatology, 2011, 27(6): 611-613.
[17]	Huang WeiShen, Yang Li. Predicting scoring system for hepatocellular carcinoma development in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2011, 27(4): 363-364.
[18]	Li Hai, Jia JiDong. Interpretation of the guideline on prevention and treatment for chronic hepatitis B (2010 version) -the goals and indications for chronic hepatitis B treatment[J]. Journal of Clinical Hepatology, 2011, 27(8): 791-793.
[19]	Jin QingLong, Wang ZhongFeng, Yan HongQing, Niu JunQi. The study of the change in creatine kinase in patients with chronic hepatitis B during the antiviral treatment with Telbivudine and Lamivudine[J]. Journal of Clinical Hepatology, 2011, 27(2): 143-144+156.
[20]	Li Zhi, Yan HongMei, Xue FaXuan, Wang Tong, Liang Qun, Xu Huan, Li ZhangChun. Short-term clinical effect of telbivudine in the treatment chronic hepatitis B[J]. Journal of Clinical Hepatology, 2009, 25(6): 420-421+426.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (679) PDF downloads(141)

Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.10.017

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2019.10.017

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content